Table 1. Baseline data for nephrotic patients with congenital red hair color, and duration and outcomes of ACTH therapy.
| Patient | Gender | Age (y) | Renal biopsy | Previous Immunosuppression | Steroid response | Duration of ACTH therapy (months) | ACEI/ARB | uACR (mg/mmol) |
eGFR (ml/min/1.73 m2) |
Outcome | Adverse effects | MC1R mutations | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Before | After | Before | After | |||||||||||
| 1 | Male | 65 | iMN (II) | Steriods | Steroid resistance | 7 | Yes | 485 | 0.85 | 54 | 56 | Complete remission | No | D84E |
| 2 | Female | 45 | iMN (II~III) | Steriods + Tacrolimus | Steroid resistance | 21 | Yes | 244 | 7.5 | 92 | 113 | Complete remission | No | R151C |
| 3 | Male | 18 | FSGS | Steriods + MMF, Cyclosporine, Tacrolimus | Steroid resistance | >97 | Yes | 983 | 1.9 | <20 | 63 | Complete remission | Pulmonary aspergillosis | R151C |
| 4 | Male | 53 | FSGS | Steriods + Cyclosporine, Tacrolimus | Steroid resistance | 52 | Yes | 300 | 1.4 | 59 | 72 | Complete remission | No | R151C |
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin II receptor blockers; eGFR, estimated glomerular filtration rate; FSGS, Focal segmental glomerulosclerosis; iMN, idiopathic membranous nephropathy; MMF, mycophenolate mofetil; uACR, urinary albumin to creatinine ratio.